Multi-center experience with novel transplant conditioning regimens that incorporate 90Y ibritumomab tiuxetan (Zevalin®) Radioimmunotherapy (RIT) for autologous and allogeneic stem cell transplantation in patients with poor-risk B-cell non-hodgkin's lymphoma (NHL):: Targeted intensification and elimination of total body irradiation

被引：0
|
作者：
Molina, A
Nademanee, A
Winter, JN
Fung, HC
Inwards, DJ
Multani, P
Khouri, I
Raubitschek, A
White, CA
机构：
[1] IDEC Pharm, Med Affairs, San Diego, CA USA
[2] City Hope Canc Ctr, Dept Hematol & Bone Marrow Transplantat, Duarte, CA USA
[3] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA
[4] Mayo Clin & Mayo Fdn, Sch Med, Rochester, MN USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2003年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 40 条
  • [1] The City of Hope experience with novel transplant regimens that incorporate standard and escalated dose 90Yttrium ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin's lymphoma (NHL):: Targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
    Nademanee, A
    Fung, H
    Molina, A
    Krishnan, A
    Rodriguez, R
    Popplewell, L
    Spielberger, RT
    O'Donnell, M
    Snyder, D
    Parker, P
    Stein, A
    Kogut, N
    Falk, P
    Sahebi, F
    Zain, J
    Saville, W
    Raubitschek, A
    Forman, SJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 28 - 28
  • [2] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in the treatment of non-Hodgkin's lymphoma (NHL):: Incorporation into autologous stem cell transplantation (ASCT) regimens
    Nademanee, A
    Krishnan, A
    Fung, H
    Raubitschek, A
    Forman, S
    Molina, A
    ANNALS OF ONCOLOGY, 2005, 16 : 100 - 100
  • [3] Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT)
    Jacobs, SA
    McCook, B
    Torok, F
    Avril, N
    Vidnovic, N
    Joyce, J
    Molina, A
    BLOOD, 2004, 104 (11) : 395B - 395B
  • [4] Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Wiseman, G
    Conti, P
    Vo, K
    Schilder, RJ
    Foster, P
    Gordon, LI
    Emmanouilides, C
    Silverman, D
    Witzig, TE
    Molina, A
    BLOOD, 2004, 104 (11) : 721A - 721A
  • [5] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Experience with yttrium 90 ibritumomab tiuxetan after autologous stem cell transplant (ASCT) in patients with non-Hodgkin's lymphoma (NHL).
    Joyce, J
    Schuster, MW
    McCook, B
    Torok, F
    Avril, N
    Vidnovic, N
    Jacobs, SA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 602S - 602S
  • [7] Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).
    Khouri, Issa F.
    Saliba, Rima M.
    Hosing, Chitra
    Valverde, Rosamar
    Erwin, William D.
    Fayad, Luis
    Maadani, Farzaneh
    Korbling, Martin J.
    Okoroji, Grace-Julia
    Stachowiak, Anne M.
    Samuels, Barry I.
    Anderlini, Paolo
    Couriel, Daniel R.
    de Lima, Marcos
    Giralt, Sergio
    Popat, Uday
    Kebriaei, Partow
    Ueno, Naoto T.
    Qazilbash, Muzaffar H.
    McLaughlin, Peter W.
    Hagemeister, Fredrick B.
    Younes, Anas
    Podoloff, Donald A.
    Champlin, Richard E.
    BLOOD, 2006, 108 (11) : 98A - 98A
  • [8] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [9] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, IW
    Kahl, BS
    Frey, E
    Bianco, JA
    Hammes, RJI
    Billing, LS
    Swinnen, LJ
    Sgouros, G
    Wahl, RL
    BLOOD, 2004, 104 (11) : 256A - 256A
  • [10] Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin) in treatment of CD 20 positive mature B-cell non-Hodgkin's lymphoma: Initial experience.
    Khan, H. A. K.
    Shemmari, S. A. S.
    Sajnani, K. S.
    Mohannadi, S. A. M.
    Huda, F. A. H.
    Usmani, S. U.
    Abdulla, M. M. A.
    Mahmoud, S. A. D.
    Javaid, A. J.
    Sahi, Z. M. S.
    Wael, W. A.
    Ghaniem, I. G.
    Parekh, H. G. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S168 - S168
1234